Skip to search form
Skip to main content
Skip to account menu
Semantic Scholar
Semantic Scholar's Logo
Search 227,740,528 papers from all fields of science
Search
Sign In
Create Free Account
odanacatib
Known as:
(2S)-N-(1-Cyanocyclopropyl)-4-fluoro-4-methyl-2-(((1S)-2,2,2-trifluoro-1-(4'-(methylsulfonyl)(1,1'-biphenyl)-4-yl)ethyl)amino)pentanamide
An inhibitor of cathepsin K with potential anti-osteoporotic activity. Odanacatib selectively binds to and inhibits the activity of cathepsin K…
Expand
National Institutes of Health
Create Alert
Alert
Related topics
Related topics
4 relations
Broader (1)
Biphenyl Compounds
Bone Resorption Inhibition
Cathepsins
Narrower (1)
MK-0822
Papers overview
Semantic Scholar uses AI to extract papers important to this topic.
Review
2018
Review
2018
Certainties and Uncertainties About Denosumab Discontinuation
E. Tsourdi
,
M. Zillikens
Calcified Tissue International
2018
Corpus ID: 49292151
The subjects of optimal duration of osteoporosis treatment consequences of stopping osteoporosis
2017
2017
Romosozumab - Promising or Practice Changing?
C. Rosen
New England Journal of Medicine
2017
Corpus ID: 205080830
Over the past decade, the osteoporosis landscape has changed. Even though more treatment options are available, fewer…
Expand
2017
2017
Identification of mouse cathepsin K structural elements that regulate the potency of odanacatib.
S. Law
,
Pierre-Marie Andrault
,
+4 authors
D. Brömme
Biochemical Journal
2017
Corpus ID: 8738948
Cathepsin K (CatK) is the predominant mammalian bone-degrading protease and thus an ideal target for antiosteoporotic drug…
Expand
Review
2014
Review
2014
Future directions for new medical entities in osteoporosis.
S. Ferrari
Best practice & research. Clinical endocrinology…
2014
Corpus ID: 26856020
2013
2013
Effect of the cathepsin K inhibitor odanacatib administered once weekly on bone mineral density in Japanese patients with osteoporosis—a double-blind, randomized, dose-finding study
T. Nakamura
,
M. Shiraki
,
+8 authors
S. Uchida
Osteoporosis International
2013
Corpus ID: 24622146
SummaryThe efficacy and safety of oral placebo or odanacatib 10, 25, or 50 mg once weekly for 52 weeks were evaluated in a double…
Expand
2012
2012
Effects of Odanacatib on Bone Mineralization Density Distribution in Thoracic Spine and Femora of Ovariectomized Adult Rhesus Monkeys: A Quantitative Backscattered Electron Imaging Study
N. Fratzl-Zelman
,
P. Roschger
,
J. Fisher
,
L. Duong
,
K. Klaushofer
Calcified Tissue International
2012
Corpus ID: 17930720
Odanacatib (ODN) has been developed as a selective inhibitor of cathepsin K, the major cysteine protease in osteoclasts. In adult…
Expand
2010
2010
The discovery of MK-0674, an orally bioavailable cathepsin K inhibitor.
Elise Isabel
,
K. Bateman
,
+28 authors
W. Black
Bioorganic & Medicinal Chemistry Letters
2010
Corpus ID: 30445824
Review
2010
Review
2010
New treatment modalities in osteoporosis.
E. Canalis
Endocrine Practice
2010
Corpus ID: 13527226
OBJECTIVE To describe recently discovered agents for the management of osteoporosis. METHODS A literature review (PubMed search…
Expand
2009
2009
Odanacatib, a cathepsin K inhibitor for the treatment of osteoporosis and other skeletal disorders associated with excessive bone remodeling.
Lewiecki Em
2009
Corpus ID: 68008537
Abstract Odanacatib (MK-0822, MK-822) is an orally administered cathepsin K inhibitor being developed by Merck & Co Inc, under…
Expand
2009
2009
New opportunities in the management of prostate cancer–related bone complications
Matthew R. Smith
,
G. Brown
,
F. Saad
2009
Corpus ID: 71246425
By clicking accept or continuing to use the site, you agree to the terms outlined in our
Privacy Policy
(opens in a new tab)
,
Terms of Service
(opens in a new tab)
, and
Dataset License
(opens in a new tab)
ACCEPT & CONTINUE
or Only Accept Required